Spots Global Cancer Trial Database for akt inhibitor mk2206
Every month we try and update this database with for akt inhibitor mk2206 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | NCT01519427 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | Akt inhibitor M... selumetinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | NCT01294306 | Adenosquamous L... Bronchioloalveo... Large Cell Lung... Lung Adenocarci... Recurrent Non-S... Squamous Cell L... | Akt Inhibitor M... Erlotinib Hydro... Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma | NCT01604772 | Recurrent Oral ... Recurrent Saliv... Salivary Gland ... Stage IVA Major... Stage IVA Oral ... Stage IVB Major... Stage IVB Oral ... Stage IVC Major... Stage IVC Oral ... | Akt Inhibitor M... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | NCT01239342 | Metastatic Kidn... Recurrent Renal... Stage III Renal... Stage IV Renal ... | Akt Inhibitor M... Everolimus Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy | NCT01658943 | Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre... | Akt Inhibitor M... Fluorouracil Oxaliplatin Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT01253447 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... | Akt inhibitor M... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT01283035 | Ovarian Sarcoma Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Akt Inhibitor M... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01369849 | Chronic Lymphoc... Recurrent Small... Refractory Chro... | Akt Inhibitor M... Bendamustine Hy... Laboratory Biom... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery | NCT01859182 | Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Localized Unres... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage II Gallbl... Stage IIIA Gall... Stage IIIB Gall... Stage IVA Gallb... Stage IVB Gallb... Unresectable Ex... | selumetinib Akt inhibitor M... laboratory biom... pharmacogenomic... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer | NCT01251861 | Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | Akt Inhibitor M... Bicalutamide Clinical Observ... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer | NCT01263145 | Adult Solid Neo... Recurrent Breas... Stage IV Breast... | Akt Inhibitor M... Laboratory Biom... Paclitaxel Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | NCT01239342 | Metastatic Kidn... Recurrent Renal... Stage III Renal... Stage IV Renal ... | Akt Inhibitor M... Everolimus Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | NCT01245205 | HER2-positive B... Male Breast Can... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Unspecified Adu... | Akt inhibitor M... lapatinib ditos... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01783171 | Pancreatic Aden... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Akt Inhibitor M... Dinaciclib Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT01253447 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... | Akt inhibitor M... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | NCT01245205 | HER2-positive B... Male Breast Can... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Unspecified Adu... | Akt inhibitor M... lapatinib ditos... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery | NCT01425879 | Advanced Adult ... Localized Non-R... Recurrent Adult... Recurrent Gallb... Stage IV Distal... Stage IV Gallbl... Unresectable Ex... Unresectable Ga... | Akt Inhibitor M... Diagnostic Labo... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01369849 | Chronic Lymphoc... Recurrent Small... Refractory Chro... | Akt Inhibitor M... Bendamustine Hy... Laboratory Biom... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT01481129 | Diffuse Large B... | Akt Inhibitor M... Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer | NCT01344031 | Estrogen Recept... Invasive Breast... Recurrent Breas... Stage IV Breast... | Akt Inhibitor M... Anastrozole Fulvestrant Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy | NCT01658943 | Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre... | Akt Inhibitor M... Fluorouracil Oxaliplatin Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer | NCT01260701 | Adenocarcinoma ... Diffuse Gastric... Gastric Intesti... Gastric Mixed A... Recurrent Gastr... | Akt Inhibitor M... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer | NCT01260701 | Adenocarcinoma ... Diffuse Gastric... Gastric Intesti... Gastric Mixed A... Recurrent Gastr... | Akt Inhibitor M... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma | NCT01604772 | Recurrent Oral ... Recurrent Saliv... Salivary Gland ... Stage IVA Major... Stage IVA Oral ... Stage IVB Major... Stage IVB Oral ... Stage IVC Major... Stage IVC Oral ... | Akt Inhibitor M... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer | NCT01307631 | Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Recurrent Uteri... | Akt Inhibitor M... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | NCT01480154 | Advanced Malign... Stage III Cutan... Stage III Prost... Stage III Renal... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Stage IV Prosta... Stage IV Renal ... | Akt Inhibitor M... Hydroxychloroqu... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | NCT01802320 | Colon Mucinous ... Colon Signet Ri... Rectal Mucinous... Rectal Signet R... Recurrent Colon... Recurrent Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... | Akt Inhibitor M... Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
